EU suspension for Servier's Protelos on the cards
This article was originally published in Scrip
The EU's pharmacovigilance committee PRAC has recommended to the CHMP that the marketing authorization for Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) be suspended. The product's fate now awaits the CHMP's next meeting on 20-23 January.
You may also be interested in...
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.